Neogenomics (NEO) Net Equity Issued and Repurchased (2010 - 2026)

Neogenomics (NEO) has 15 years of Net Equity Issued and Repurchased data on file, last reported at $2.1 million in Q2 2026.

• Quarterly Net Equity Issued and Repurchased rose 58.69% year-over-year to $2.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $448000.0 (down 89.15% YoY) and the FY2025 annual result came in at $962000.0, down 79.29% from the prior year.
• Net Equity Issued and Repurchased climbed to $2.1 million in Q2 2026, from -$338000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $6.4 million in Q1 2022 to a low of -$1.7 million in Q3 2025.
• A 5-year average of $1.4 million and a median of $1.3 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased surged 2013.98% — and 2025, when it sank 247.41%.
• Tracing NEO's Net Equity Issued and Repurchased over 5 years: stood at $1.9 million in 2022, then plunged by 31.28% to $1.3 million in 2023, then plunged by 46.08% to $687000.0 in 2024, then plunged by 37.26% to $431000.0 in 2025, then jumped by 384.92% to $2.1 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $2.1 million (Q2 2026), -$338000.0 (Q1 2026), and $431000.0 (Q4 2025), per Business Quant data.